Katarzyna Taylor Selected Research

Erythromycin (Erycette)

1/2016

Oral administration of erythromycin decreases RNA toxicity in myotonic dystrophy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Katarzyna Taylor Research Topics

Disease

8	Myotonic Dystrophy (Dystrophia Myotonica) 08/2023 - 01/2014
2	Fragile X Tremor Ataxia Syndrome 01/2021 - 01/2021
1	Autistic Disorder (Autism) 08/2023
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2021
1	Hypoxia (Hypoxemia) 01/2020
1	Neoplasms (Cancer) 01/2020
1	Muscle Weakness 01/2019
1	Myotonia 01/2016

Drug/Important Bio-Agent (IBA)

5	RNA (Ribonucleic Acid)IBA 08/2023 - 01/2014
3	Proteins (Proteins, Gene)FDA Link 01/2021 - 12/2017
2	RNA Splicing FactorsIBA 08/2023 - 01/2019
2	3' Untranslated Regions (3' UTR)IBA 01/2016 - 01/2014
1	polyglycineIBA 01/2021
1	MicroRNAs (MicroRNA)IBA 01/2021
1	Nuclear Proteins (Protein, Nuclear)IBA 01/2021
1	5' Untranslated Regions (5' UTR)IBA 01/2021
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2020
1	Nuclear RNAIBA 01/2020
1	RNA-Binding Proteins (RNA-Binding Protein)IBA 01/2020
1	Protein Kinases (Protein Kinase)IBA 01/2019
1	Circular RNAIBA 01/2019
1	Biomarkers (Surrogate Marker)IBA 01/2019
1	2,9-diamino-1,10-phenanthrolineIBA 12/2018
1	Erythromycin (Erycette)FDA LinkGeneric 01/2016
1	Nucleic AcidsIBA 03/2015
1	Phosphotransferases (Kinase)IBA 01/2014

Therapy/Procedure

1	Oral Administration 01/2016